# Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT05896228** · PHASE2 · RECRUITING · sponsor: **Benjamin T Diamond, MD** · enrollment: 30 (estimated)

## Conditions studied

- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma

## Interventions

- **DRUG:** Iberdomide
- **DRUG:** Carfilzomib
- **DRUG:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Montelukast

## Key facts

- **NCT ID:** NCT05896228
- **Lead sponsor:** Benjamin T Diamond, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2029-03-01
- **Final completion:** 2031-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896228, "Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05896228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*